Kijsta K2 Softgel Capsule is a combination pharmaceutical formulation containing Calcitriol (0.25 mcg), Calcium Carbonate (250 mg), and Vitamin K2-7 (45 mcg), designed to support bone health and calcium metabolism. Calcitriol, the active form of vitamin D3, plays a critical role in enhancing intestinal absorption of calcium and phosphate, thereby aiding in the maintenance of adequate serum calcium levels essential for normal bone mineralization. Calcium Carbonate serves as a calcium supplement to prevent or treat calcium deficiencies, contributing to the structural integrity of bone tissue. Vitamin K2-7 (menaquinone-7) is instrumental in activating osteocalcin, a protein necessary for binding calcium to the bone matrix, thus promoting bone strength and reducing the risk of fractures. This synergistic combination is particularly beneficial in conditions such as osteoporosis, hypocalcemia, and other metabolic bone disorders where calcium homeostasis is disrupted. Kijsta K2 Softgel Capsule should be administered under medical supervision, with dosage tailored according to individual patient needs and serum calcium levels, to avoid hypercalcemia or other adverse effects. It is contraindicated in patients with hypercalcemia, vitamin D toxicity, or hypersensitivity to any component. Regular monitoring of serum calcium and renal function is recommended during therapy.